SR-9011 (REV-ERB Agonist) + GW-0742 (Fitorine) | Metabolic Research UK

Energy Metabolism Research Set

The BioPlex Energy Metabolism Research Set combines SR-9011 (REV-ERB Agonist) 50×15mg and GW-0742 (Fitorine) 50×15mg, bringing together two synthetic research compounds associated with distinct nuclear-receptor pathways involved in metabolic and cellular-energy research. The set contains one pot of each compound and provides a structured format for comparative laboratory investigation of REV-ERB-associated signalling alongside PPARδ-associated research.

SR-9011 is associated primarily with experimental investigation of REV-ERBα and REV-ERBβ. These nuclear receptors participate in transcriptional networks linking circadian regulation with metabolic processes, making them important targets in research examining the relationship between biological timing, gene expression and cellular metabolism.

GW-0742 represents a separate molecular pathway. Presented within the BioPlex range as Fitorine, GW-0742 is associated primarily with peroxisome proliferator-activated receptor delta, commonly abbreviated PPARδ. Research involving this receptor has examined transcriptional pathways associated with lipid handling, fatty-acid metabolism and cellular-energy regulation.

Neither SR-9011 nor GW-0742 is scientifically classified as a selective androgen receptor modulator. Although compounds of this type may appear commercially alongside SARMs, their molecular targets and pharmacological classifications are different from androgen-receptor ligands such as RAD-140 or MK-2866.

The Energy Metabolism Research Set therefore creates a two-pathway laboratory research format rather than pairing compounds with an identical molecular target.

Each compound remains individually identified, enabling researchers to investigate REV-ERB and PPARδ-associated pathways independently while comparing predefined metabolic and transcriptional endpoints within a controlled research framework.

How SR-9011 and GW-0742 Work Together

SR-9011 and GW-0742 provide an interesting comparative research pairing because each is associated with a different nuclear-receptor system connected with metabolic regulation. SR-9011 is associated with REV-ERB research, whereas GW-0742 is associated primarily with PPARδ.

REV-ERBα and REV-ERBβ participate in the molecular machinery responsible for circadian transcriptional regulation. Circadian biology extends beyond the sleep-wake cycle and involves rhythmic changes in gene expression across numerous cellular and metabolic processes. This has made REV-ERB signalling an important area of experimental investigation.

SR-9011 has been used as a synthetic research compound within this field, allowing researchers to investigate relationships between REV-ERB-associated signalling, circadian transcription and predefined metabolic markers.

GW-0742 provides a different research mechanism. PPARδ belongs to the nuclear-receptor superfamily and participates in transcriptional regulation of pathways involving lipid utilisation, fatty-acid metabolism and cellular-energy processes.

Placing these two compounds within the same research set therefore allows researchers to consider two distinct transcriptional systems within a broader energy-metabolism framework.

The combination does not establish that SR-9011 and GW-0742 act synergistically. Nor does activity involving one receptor system demonstrate that the other pathway will respond in a particular manner. Cellular metabolism is controlled through interconnected regulatory networks, and experimental outcomes can vary according to model, concentration, receptor expression, exposure and methodology.

The research value instead comes from pathway comparison. SR-9011 provides the REV-ERB-associated component, while GW-0742 provides the PPARδ-associated component.

This creates a structured format for investigating different aspects of metabolic transcriptional regulation while maintaining appropriate compound-specific controls and scientifically accurate classification.

SR-9011 (REV-ERB Agonist) 50×15mg

SR-9011 is a synthetic research compound associated with experimental investigation of the nuclear receptors REV-ERBα and REV-ERBβ. It has been used within research examining circadian transcription, metabolic regulation and the molecular relationship between biological timing and cellular processes.

REV-ERB receptors belong to the nuclear-receptor superfamily and participate in transcriptional networks forming part of the molecular circadian clock. Their regulatory activity connects circadian biology with broader areas of metabolism and gene expression.

This relationship has generated scientific interest in synthetic ligands capable of experimentally influencing REV-ERB-associated pathways. SR-9011 has consequently been investigated in experimental systems examining metabolic, transcriptional and circadian-associated endpoints.

However, classification as a REV-ERB-associated research compound does not mean that every observed experimental response can automatically be attributed exclusively to REV-ERB signalling. Compound concentration, cellular environment, experimental model and potential off-target activity must be considered when interpreting findings.

SR-9011 is also not a SARM. Its principal research classification concerns REV-ERB-associated nuclear-receptor biology rather than selective modulation of the androgen receptor.

Within the Energy Metabolism Research Set, SR-9011 provides the circadian and REV-ERB-associated component of the pairing.

This can be investigated independently before predefined observations are compared with the PPARδ-associated research profile of GW-0742.

Maintaining this distinction is important because both compounds may be grouped commercially within broader research-compound categories despite having different molecular targets.

SR-9011 therefore contributes a distinct transcriptional research pathway to the set, supporting comparative investigation of metabolic signalling without treating different classes of research compounds as pharmacologically interchangeable.

GW-0742 (Fitorine) 50×15mg

GW-0742, presented within the BioPlex research range as Fitorine, is a synthetic research compound associated primarily with peroxisome proliferator-activated receptor delta, commonly abbreviated PPARδ.

PPARδ belongs to the nuclear-receptor superfamily and functions as a transcriptional regulator. Research involving this receptor has examined gene-expression pathways associated with lipid handling, fatty-acid metabolism, cellular-energy regulation and related areas of metabolic biology.

GW-0742 has consequently been used experimentally as a pharmacological research tool for investigating PPARδ-associated signalling and determining how receptor modulation corresponds with changes in predefined molecular and cellular endpoints.

Its molecular classification clearly distinguishes it from SR-9011. Although both compounds can be studied within the broad field of metabolic regulation, SR-9011 is associated with REV-ERB research whereas GW-0742 provides the PPARδ-focused component.

GW-0742 is also not a selective androgen receptor modulator. Its inclusion within commercial research-compound ranges alongside SARMs should not be interpreted as evidence of androgen-receptor activity.

Within the Energy Metabolism Research Set, GW-0742 therefore provides a complementary but mechanistically distinct research pathway.

Researchers can investigate PPARδ-associated observations independently before comparing selected metabolic and transcriptional markers with those generated within SR-9011 experimental systems.

This approach preserves the pharmacological identity of each compound rather than assuming that shared relevance to metabolic research means identical biological activity.

Concentration, exposure, receptor expression, cellular environment and potential off-target effects remain important considerations when interpreting experimental findings.

Together with SR-9011, GW-0742 creates a two-compound framework for comparative investigation of nuclear-receptor pathways associated with metabolic and cellular-energy research.

Explore Related Research Compounds

Continue exploring related metabolic and nuclear-receptor research compounds from the BioPlex capsule range.

View SR-9011 REV-ERB Agonist 50×15mg Research Capsules ⟶

View GW-0742 Fitorine 50×15mg Research Capsules ⟶

View SR-9009 Stenabolic 50×15mg Research Capsules ⟶

Explore BioPlex Research Information

Access BioPlex research guidance, compound classification and the complete research product range.

Read the Complete SARMs UK Research Compound Guide ⟶

Explore the BioPlex SARMs & Research Compound Range ⟶

View All BioPlex Research Products ⟶

Explore Related Research Articles

Continue your research with BioPlex articles covering metabolic research compounds, nuclear-receptor signalling and the scientific classification of compounds sold alongside SARMs.

Read the Complete SARMs UK Research Compound Guide ⟶

Explore All BioPlex SARMs Research Articles ⟶

Disclaimer

For research purposes only. Not for human consumption